Automate Your Wheel Strategy on AMGN
With Tiblio's Option Bot, you can configure your own wheel strategy including AMGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
Read More
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
Published: April 26, 2025 by: The Motley Fool
Sentiment: Positive
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts.
Read More
Amgen to expand Ohio biotech manufacturing plant
Published: April 25, 2025 by: Reuters
Sentiment: Positive
Amgen on Friday announced a $900 million expansion of its Ohio biotech manufacturing facility, becoming the latest in a string of drugmakers pledging to increase U.S. capacity amid Trump administration threats of potential import tariffs.
Read More
AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
Published: April 25, 2025 by: PRNewsWire
Sentiment: Neutral
Total Investment in the State to Exceed $1.4 Billion, 750 U.S. Jobs THOUSAND OAKS, Calif. , April 25, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $900 million expansion of its Ohio manufacturing facility, bringing the total number of jobs created to 750 and the total investment in Central Ohio to over $1.4 billion.
Read More
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
Published: April 22, 2025 by: The Motley Fool
Sentiment: Positive
When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. However, you don't necessarily have to sacrifice growth for safety.
Read More
Final Trades: Take-Two Interactive, Franco-Nevada, Amgen and the 10-Year Treasury
Published: April 21, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Here's Why Amgen (AMGN) is a Strong Value Stock
Published: April 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Trump Says Pharmaceutical Tariffs Coming in Near Future
Published: April 14, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Read More
Trump says US pharma tariffs coming in not-too-distant future
Published: April 14, 2025 by: Reuters
Sentiment: Negative
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Read More
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
Published: April 11, 2025 by: CNBC
Sentiment: Negative
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Read More
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
Published: April 11, 2025 by: PRNewsWire
Sentiment: Neutral
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, Calif. , April 11, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or after a single line of platinum-based chemotherapy met its primary endpoint at a planned interim analysis.
Read More
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Read More
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Published: April 09, 2025 by: WSJ
Sentiment: Negative
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Read More
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
Read More
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
Read More
AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Positive
The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.
Read More
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Amgen (AMGN) concluded the recent trading session at $310.09, signifying a +1.44% move from its prior day's close.
Read More
US FDA approves expanded use of Amgen's rare disease drug
Published: April 03, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday.
Read More
Final Trades: Amgen, Sabra Health Care and Kinsale Capital Group
Published: April 03, 2025 by: CNBC Television
Sentiment: Neutral
(OPTIMIZED VIDEO SPECIFIC DESCRIPTION)
Read More
Got $5,000? These 3 Nasdaq Stocks Are Dirt Cheap Buys Right Now
Published: April 03, 2025 by: The Motley Fool
Sentiment: Negative
As of Monday, the Nasdaq Composite index had tumbled more than 11% since the start of the year. The outlook for the economy is worrisome, as trade wars and promised tariffs could lead to disaster for many businesses.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
GILD or AMGN: Which Is the Better Value Stock Right Now?
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Trade Tracker: Kevin Simpson buys Howmet, buys more Amgen
Published: March 28, 2025 by: CNBC Television
Sentiment: Neutral
Kevin Simpson, Capital Wealth Planning founder and CIO, joins CNBC's "Halftime Report" to detail his latest portfolio buys.
Read More
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Biopharma firms with foreign exposure face disruption as Trump's tariffs loom
Published: March 27, 2025 by: Proactive Investors
Sentiment: Negative
The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.
Read More
Trade Tracker: Karen Firestone buys Amgen and buys more HealthEquity
Published: March 26, 2025 by: CNBC Television
Sentiment: Positive
Karen Firestone, executive chairman at Aureus Asset Management, joins CNBC's "Halftime Report" to detail her latest stock purchases. The Investment Committee debate healthcare and biotech companies.
Read More
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
Read More
Prediction: These 2 Stocks Will Outperform the Market Through 2030
Published: March 18, 2025 by: The Motley Fool
Sentiment: Positive
Equity markets can move every which way from one day to the next. The more we extend our horizon, the more likely it is that stocks will provide juicy returns.
Read More
About Amgen Inc. (AMGN)
- IPO Date 1983-06-17
- Website https://www.amgen.com
- Industry Drug Manufacturers - General
- CEO Robert A. Bradway
- Employees 28000